Authored by Richard Martin Partner Ihar Nekrashevich Science Analyst Sam Comb Science Analyst
As well as stimulating insulin release, GLP-1R agonists promote satiety and reduce food intake, leading to weight loss
Stay well hydrated and follow standard heat management practices during summer training regardless of which supplement you use
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
At Formation we use only human-grade compounds from licensed pharmacies, and we hold SSRP and ISSCA certification for working with these molecules
You are encouraged to report any adverse side effects of prescription drugs to the FDA